Actavis Inc (ACT): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Actavis ( ACT) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.2%. By the end of trading, Actavis rose $2.27 (1.9%) to $124.35 on light volume. Throughout the day, 1,250,461 shares of Actavis exchanged hands as compared to its average daily volume of 1,714,000 shares. The stock ranged in a price between $122.04-$125.32 after having opened the day at $122.08 as compared to the previous trading day's close of $122.08. Other companies within the Drugs industry that increased today were: Transition Therapeutics ( TTHI), up 38.5%, Ocera Therapeutics ( OCRX), up 32.5%, Biosante Pharmaceuticals ( BPAX), up 9.3% and Celsion Corporation ( CLSN), up 7.9%.

Actavis, Inc., an integrated specialty pharmaceutical company, engages in developing, manufacturing, marketing, selling, and distributing generic, branded generic, brand, biosimilar, and over-the-counter pharmaceutical products worldwide. Actavis has a market cap of $15.7 billion and is part of the health care sector. Shares are up 42.0% year to date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Actavis a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Actavis as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Senesco Technologies ( SNTI), down 11.6%, ImmuCell Corporation ( ICCC), down 10.8%, TG Therapeutics ( TGTX), down 10.3% and pSivida ( PSDV), down 8.1% , were all laggards within the drugs industry with Questcor Pharmaceuticals ( QCOR) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%